Literature DB >> 6354792

Impact of insulin or tolbutamide treatment on 14C-arachidonic acid conversion to prostacyclin and/or thromboxane in lungs, aortas, and platelets of streptozotocin-induced diabetic rats.

M A Valentovic, W C Lubawy.   

Abstract

Diabetes is associated with a dramatic increase in the risk of thrombotic and atherosclerotic disease. The underlying factors responsible for this predisposition as well as the mechanisms involved have yet to be elucidated. Two endogenous substances, prostacyclin (PGI2) and thromboxane (TXA2), have recently been shown to possess significant vascular and thrombotic activity and are known to be altered in atherosclerosis, thrombotic conditions, and diabetes. We determined the conversion of 14C-arachidonic acid (AA) to PGI2 and TXA2 by lungs, aortas, and platelets obtained from chemically induced diabetic rats. In addition, we investigated the ability of insulin or tolbutamide to reverse these changes. Streptozotocin (STZ)-injected rats developed blood glucose levels 2-4 times that seen in normoglycemic controls. Intact perfused lungs isolated from rats beginning 7 days after STZ treatment synthesized 22-30% less PGI2 from 14C-AA. The ratio of PGI2/TXA2 was decreased in the diabetic rat lungs and was inversely proportional to plasma glucose levels at the time of death. Platelet TXA2 generation was increased 67% above control in diabetic rats while aortic PGI2 generation was decreased 28% below normoglycemic controls. Ten-day treatment with NPH insulin 20 U/kg s.c. in STZ-pretreated rats lowered plasma glucose toward normoglycemia more effectively than tolbutamide 200 mg/kg orally. Partial correction of the decreased pulmonary PGI2/TXA2 ratio seen in diabetic rats was produced by insulin and tolbutamide in proportion to their ability to lower blood glucose. At the doses employed, insulin caused aortic PI2 and platelet TXA2 generation from 14C-AA to approach that seen in mormoglycemic controls more effectively than tolbutamide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354792     DOI: 10.2337/diab.32.9.846

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  Changes in cardiovascular sensitivity of alloxan-treated diabetic rats to arachidonic acid.

Authors:  A L Boura; W C Hodgson; R G King
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

2.  Renal vascular responsiveness to arachidonic acid in experimental diabetes.

Authors:  J Quilley; J C McGiff
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

3.  Endothelium-dependent increase in vascular sensitivity to phenylephrine in long-term streptozotocin diabetic rat aorta.

Authors:  K S Chang; W C Stevens
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

Review 4.  Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.

Authors:  R Huupponen
Journal:  Med Toxicol       Date:  1987 May-Jun

5.  Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density lipoproteins in experimental diabetes.

Authors:  I Ginon; C Talussot; G Ponsin; M Ciavatti
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

6.  Relationship between vascular adrenergic receptors and prostaglandin biosyntheses in canine diabetic coronary arteries.

Authors:  M Z Koltai; P Rösen; P Hadházy; G Ballagi-Pordány; A Köszeghy; G Pogátsa
Journal:  Diabetologia       Date:  1988-09       Impact factor: 10.122

7.  Effects of prostaglandin E2 and indomethacin on 25-hydroxyvitamin D3-1 alpha-hydroxylase activity in isolated kidney cells of normal and streptozotocin-induced diabetic rats.

Authors:  H Kurose; Y M Sonn; A Jafari; S J Birge; L V Avioli
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

8.  Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing.

Authors:  Lucreţia Udrescu; Laura Sbârcea; Alexandru Topîrceanu; Alexandru Iovanovici; Ludovic Kurunczi; Paul Bogdan; Mihai Udrescu
Journal:  Sci Rep       Date:  2016-09-07       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.